Wedbush Forecasts Strong Price Appreciation for Opus Genetics (NASDAQ:IRD) Stock

Opus Genetics (NASDAQ:IRD) had its price objective boosted by investment analysts at Wedbush from $8.00 to $10.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s target price suggests a potential upside of 98.81% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Craig Hallum set a $9.00 price objective on shares of Opus Genetics and gave the stock a “buy” rating in a research report on Wednesday. B. Riley Financial began coverage on shares of Opus Genetics in a research report on Wednesday, December 10th. They set a “buy” rating and a $9.00 target price for the company. Lifesci Capital upgraded shares of Opus Genetics to a “strong-buy” rating in a research report on Thursday, February 12th. Piper Sandler initiated coverage on shares of Opus Genetics in a research note on Tuesday, November 25th. They set an “overweight” rating and a $7.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Opus Genetics in a research note on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $9.25.

Opus Genetics Stock Up 3.9%

Opus Genetics stock opened at $5.03 on Thursday. Opus Genetics has a fifty-two week low of $0.65 and a fifty-two week high of $5.30. The firm has a market capitalization of $346.87 million, a price-to-earnings ratio of -6.13 and a beta of 0.45. The stock’s fifty day moving average is $3.19 and its two-hundred day moving average is $2.32. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.23 and a current ratio of 1.23.

Insiders Place Their Bets

In other news, Director Cam Gallagher bought 83,000 shares of Opus Genetics stock in a transaction on Monday, December 29th. The shares were bought at an average cost of $1.97 per share, for a total transaction of $163,510.00. Following the acquisition, the director owned 83,000 shares in the company, valued at approximately $163,510. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On Opus Genetics

A number of hedge funds and other institutional investors have recently modified their holdings of IRD. Nantahala Capital Management LLC raised its position in shares of Opus Genetics by 42.9% in the fourth quarter. Nantahala Capital Management LLC now owns 4,781,330 shares of the company’s stock valued at $9,610,000 after buying an additional 1,435,407 shares during the last quarter. BIOS Capital Management LP grew its stake in Opus Genetics by 270.1% in the 2nd quarter. BIOS Capital Management LP now owns 3,683,429 shares of the company’s stock worth $3,462,000 after acquiring an additional 2,688,180 shares during the period. Balyasny Asset Management L.P. purchased a new stake in Opus Genetics in the 4th quarter worth approximately $5,463,000. Millennium Management LLC acquired a new position in Opus Genetics in the 4th quarter valued at $4,025,000. Finally, Mink Brook Asset Management LLC raised its holdings in Opus Genetics by 34.5% in the 4th quarter. Mink Brook Asset Management LLC now owns 1,665,631 shares of the company’s stock valued at $3,348,000 after acquiring an additional 427,684 shares during the last quarter. 14.97% of the stock is currently owned by hedge funds and other institutional investors.

Opus Genetics News Summary

Here are the key news stories impacting Opus Genetics this week:

• Positive Sentiment: Multiple firms raised price targets and reiterated positive ratings (supports upside momentum). Chardan raised its target to $11 with a Buy rating. Chardan price target raise
• Positive Sentiment: Wedbush boosted its target to $10 and kept an Outperform rating—another endorsement from a sell‑side shop. Wedbush price target raise
• Positive Sentiment: BTIG raised its price target to $12 (from $7) and maintained a Buy—adds to the cluster of higher targets that can drive investor interest. BTIG note
• Positive Sentiment: Clinical update: Opus provided progress on its Nyxol (oxymetazoline) clinical program (Phase 3 presbyopia/night‑vision studies), which is a near‑term catalyst investors watch for regulatory/market readthroughs. Clinical trial update
• Neutral Sentiment: H.C. Wainwright publicly remains constructive on Opus (keeps a Buy stance), which supports ongoing investor confidence even amid forecast changes. HC Wainwright buy rating
• Negative Sentiment: HC Wainwright cut near‑term EPS estimates across 2026 quarters and lowered FY2026 (to −$0.64) and FY2027/FY2028 forecasts substantially — this reflects a darker near‑term profitability outlook and could pressure the stock if clinical/operational progress stalls.
• Negative Sentiment: Lifesci Capital also trimmed Q1/Q2 and FY2026 EPS estimates (despite keeping a Strong‑Buy rating), signaling some analyst caution about timing or magnitude of revenue/cost assumptions.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.